Andrew J. Greenfield - 16 Dec 2022 Form 4 Insider Report for ABIOMED INC

Role
VP, CHIEF COMMERCIAL OFFICER
Signature
/s/ Marc A. Began (by power of attorney)
Issuer symbol
N/A
Transactions as of
16 Dec 2022
Net transactions value
$0
Form type
4
Filing time
20 Dec 2022, 15:05:48 UTC
Previous filing
08 Nov 2022
Next filing
27 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock, $.01 par value Award $0 +14 +0.09% $0.000000 15,977 16 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NASD Stock Option (right to buy) 5,000 16 Dec 2022 Common Stock 0 $99.62 Direct F2, F3
holding NASD Stock Option (right to buy) 6,500 16 Dec 2022 Common Stock 0 $134.51 Direct F2, F3
holding NASD Stock Option (right to buy) 4,000 16 Dec 2022 Common Stock 0 $381.97 Direct F2, F3
holding NASD Stock Option (right to buy) 7,000 16 Dec 2022 Common Stock 0 $266.39 Direct F2, F3
holding NASD Stock Option (right to buy) 4,896 16 Dec 2022 Common Stock 0 $223.90 Direct F2, F3
holding NASD Stock Option (right to buy) 2,868 16 Dec 2022 Common Stock 0 $283.88 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c)
F2 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F3 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.